PGNX Share Price

Open 6.58 Change Price %
High 6.67 1 Day 0.04 0.61
Low 6.57 1 Week 0.02 0.30
Close 6.61 1 Month -0.29 -4.20
Volume 369698 1 Year 0.55 9.08
52 Week High 11.72
52 Week Low 4.84
PGNX Important Levels
Resistance 2 6.70
Resistance 1 6.66
Pivot 6.62
Support 1 6.56
Support 2 6.52
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
DCTH 0.14 -6.67%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
SCHS 0.05 66.67%
CPSL 0.14 55.56%
LOCM 0.09 50.00%
HAUP 0.10 42.86%
SYMX 0.50 38.89%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
OPNT 11.40 24.73%
IFON 0.61 24.49%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
DCIX 0.19 -58.70%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Progenics Pharmaceuticals Inc. (NASDAQ: PGNX)

PGNX Technical Analysis 4
As on 26th Jul 2017 PGNX Share Price closed @ 6.61 and we RECOMMEND Sell for LONG-TERM with Stoploss of 7.89 & Strong Sell for SHORT-TERM with Stoploss of 6.89 we also expect STOCK to react on Following IMPORTANT LEVELS.
PGNX Target for July
1st Target up-side 7.61
2nd Target up-side 8.19
3rd Target up-side 8.77
1st Target down-side 5.97
2nd Target down-side 5.39
3rd Target down-side 4.81
PGNX Other Details
Segment EQ
Market Capital 99951264.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.progenics.com
PGNX Address
PGNX
777 Old Saw Mill River Road
Tarrytown, NY 10591
United States
Phone: 914-789-2800
Fax: 914-789-2817
PGNX Latest News
Interactive Technical Analysis Chart Progenics Pharmaceuticals Inc. ( PGNX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Progenics Pharmaceuticals Inc.
PGNX Business Profile
Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers. In gastroenterology, its first commercial product is RELISTOR subcutaneous injection. Its principal product candidate is PSMA ADC, a fully human monoclonal antibody-drug conjugate directed against prostate specific membrane antigen, a protein found at high levels on the surface of prostate cancer cells and also on the neovasculature of a number of other types of solid tumors. In January 2013, the Company acquired Molecular Insight Pharmaceuticals, Inc.